patient characteristics
Patient nr | Gender | Age | Prior treatments | Metastatic sites | Location for tumor resection | Performance status |
1 | M | 67 | DTIC, ipilimumab | Lung, adrenal, subcutaneous | Subcutaneous | 0 |
2 | M | 68 | DTIC, DC vaccination, ipilimumab | Lung, LN, spleen, subcutaneous | LN | 0 |
3 | M | 46 | Vemurafenib, ipilimumab | LN, subcutaneous | Subcutaneous | 0 |
4 | F | 44 | DTIC, vemurafenib, ipilimumab | LN, subcutaneous, soft tissue | Subcutaneous | 0 |
5 | F | 40 | DTIC, ipilimumab | Lung, subcutaneous, soft tissue | Subcutaneous | 0 |
6 | F | 43 | Temozolamide, IFN-α, DC vaccination, | LN, long, subcutaneous | Axillary LN | 0 |
Ipilimumab, vemurafenib | ||||||
7 | M | 52 | DTIC, ipilimumab | LN, lung, subcutaneous | LN | 0 |
8 | M | 40 | Peptide vaccination, ipilimumab | LN, small intestine | Large intestine | 0 |
Mesoduodenum | ||||||
9 | F | 60 | Vemurafenib, DTIC, ipilimumab | LN, subcutaneous | LN | 1 |
10 | M | 55 | DC vaccination, ipilimumab | LN, subcutaneous, liver, lung | Jejunum | 1 |
DC, dendritic cell; DTIC, dacarbazine; IFN-α, interferon-α; LN, lymph node.